tldrdailynews.com logo

Personalized mRNA vaccine plus Keytruda shows promising Phase 3 melanoma results

1 min read
Source: Ars Technica
Personalized mRNA vaccine plus Keytruda shows promising Phase 3 melanoma results
Photo: Ars Technica
TL;DR

Moderna and Merck report that adding the patient-specific mRNA cancer vaccine intismeran (mRNA-4157) to Merck’s Keytruda significantly extended recurrence-free and distant metastasis-free survival versus Keytruda alone in a Phase 3 trial of 1,137 melanoma patients. Interim results suggest meaningful benefit, with mature overall-survival data still pending; five-year Phase 2 data had previously shown substantial risk reductions. Full details will be presented at an upcoming conference.

Topics:top-newshealth#health#immunotherapy#melanoma#mrna-vaccine#personalized-cancer-therapy#phase-3-trial
Share this article
  1. mRNA cancer vaccine succeeded in Phase 3 melanoma trial, Moderna and Merck say  Ars Technica
  2. Moderna, Merck cancer vaccine shows promise in late-stage trial; Moderna stock soars 150%  cnbc.com
  3. CancerBuddy creator on ways to connect  KTVU
  4. A New mRNA Vaccine Could Prevent Melanoma From Returning  The New York Times
  5. MSD and Moderna eye cancer vaccine market debut on Phase III melanoma score  Clinical Trials Arena

Want the full story? Read the original reporting

Read on Ars Technica